No Data
No Data
BofA Securities Downgrades IGM Biosciences(IGMS.US) to Sell Rating, Cuts Target Price to $0.75
IGM Biosciences Downgraded to Underperform From Neutral at BofA
IGM Biosciences Faces Uncertainty Amid Cash Preservation and Restructuring Efforts
Morgan Stanley Sticks to Their Sell Rating for IGM Biosciences (IGMS)
Analysts Offer Insights on Healthcare Companies: Phathom Pharmaceuticals (PHAT), Aziyo Biologics (ELUT) and IGM Biosciences (IGMS)
RBC Capital Downgrades IGM Biosciences(IGMS.US) to Hold Rating, Cuts Target Price to $1.5